bioplasm

(redirected from Biogen)
Also found in: Dictionary, Wikipedia.

bi·o·plasm

(bī'ō-plazm),
Protoplasm, especially in its relation to living processes and development.
[bio- + G. plasma, thing formed]
Farlex Partner Medical Dictionary © Farlex 2012

bioplasm

A nonspecific term for germinal material within cells, which is regarded as essential to life functions—e.g., cytoplasm or protoplasm.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
At Biogen, our mission is clear: we are pioneers in neuroscience.
"Biogen delivered solid performance globally in the second quarter, and we believe we are on track for a strong year," said Michel Vounatsos, Biogen's Chief Executive Officer.
23 April 2019 - The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to the recommended acquisition of the entire issued and to be issued share capital of UK-based gene therapy specialist Nightstar Therapeutics plc (NASDAQ: NITE) by Tungsten Bidco Ltd., a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmbH, the companies said.
As part of the proposed transaction, Biogen will enter into manufacturing services agreements with Fujifilm to use the Hillerod site to produce commercial products for Biogen, such as TYSABRI, as well as other third-party products.
Under the agreement, Fujifilm will acquire the shares of Biogen's subsidiary, which holds Biogen's biologics manufacturing operations in Hillerod, Denmark, for up to USD890m in cash, subject to minimum purchase commitment guarantees and other contractual terms.
FUJIFILM Corporation, an operating company of FUJIFILM Holdings Corporation that provides technology solutions to a broad range of global industries, revealed on Monday the launch of an agreement to acquire the Biogen (Denmark) Manufacturing ApS site, located in Hillerod near Copenhagen, Denmark (Biogen Hillerod), from Biogen for a purchase price of approximately USD890m in cash, subject to customary closing conditions.
Under the agreement, Biogen will have the option to license therapies resulting from the collaboration and will be responsible for development and potential commercialisation.
Under the terms of the collaboration, Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase 11,501,153 shares of Ionis common stock at a price of $54.34 per share, at an approximately 25% cash premium, and a $375 million upfront payment.
Biogen Japan President and Representative Director Shinichi Torii commented, "Biogen is a leading company in multiple sclerosis, and approximately 40% of multiple sclerosis patients worldwide use Biogen's medicines.
Although he has been at Biogen less than a year, he is nonetheless credited with implementing key initiatives to extend the company's leadership in multiple sclerosis, expanding Biogen's penetration of key global markets and effectively preparing for the introduction of breakthrough treatments in areas of high unmet need.
Biogen sells Tysabri through a partnership with Elan Corp.